Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

Core Insights - A study published in JCO Precision Oncology indicates that Myriad Genetics' RiskScore tool effectively drives breast cancer screening recommendations tailored to individual patient risk levels [1][2][3] Group 1: Study Findings - The study titled "Association of Polygenic-based Breast Cancer Risk Prediction with Patient Management" highlights that polygenic risk predictors are relatively new, and there is limited data on their clinical application [2] - Results show that patients with a 20% or greater lifetime risk of breast cancer, as predicted by RiskScore or the Tyrer-Cuzick model, were significantly more likely to undergo enhanced screening [3][6] - The study reassures that patients receive appropriate breast cancer screening following RiskScore testing, indicating that clinicians are utilizing RiskScore results for risk-based screening recommendations [2][3] Group 2: MyRisk Hereditary Cancer Test - MyRisk Hereditary Cancer Test with RiskScore evaluates 48 genes linked to hereditary cancer risk, providing a personalized five-year and lifetime breast cancer risk assessment for patients of all ancestries [4] - The integration of family history and clinical factors, such as breast density, enhances the risk assessment process [4] Group 3: Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [5] - The company aims to improve patient care and reduce healthcare costs by leveraging molecular insights across various medical specialties [5]